ALX Oncology Holdings Inc expected to post a loss of 15 cents a share - Earnings Preview

ALX Oncology Holdings

08/08/2026 24:03

ALX Oncology Holdings Inc ALXO.OQ ALXO.O is expected to  show no change in quarterly revenue when it reports  results on November 5 (estimated) for the period ending September 30 2026

​LSEG's mean analyst estimate for ALX Oncology Holdings Inc is for a loss of 15 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts had risen by about 6.5% in the last three months. ​
Wall Street's median 12-month price target for ALX Oncology Holdings Inc is $4.00, about 90.5% above its last closing price of $2.10
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Jun. 30 2026
-0.14
-0.14
-0.12
Beat
16.3
Mar. 31 2026
-0.23
-0.19
-0.15
Beat
24.7
Dec. 31 2025
-0.35
-0.36
-0.37
Missed
-2.1​
Sep. 30 2025
-0.37
-0.37
-0.41
Missed
-11.8
​​Jun. 30 2025
-0.45
-0.45
-0.43
Beat
4.4
Mar. 31 2025
-0.45
-0.46
-0.58
Missed
-25​
Dec. 31 2024
-0.62
-0.67
-0.55
Beat
17.9
Sep. 30 2024
-0.78
-0.78
-0.58
Beat
25.6
This summary was machine generated August 7 at 23:03 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)